

Effects of rivaroxaban (Xarelto®) and apixaban (Eliquis®) on commonly used coagulation assays

Coagulation Assays		Xarelto® Effects	Eliquis® Effects
PT (sec)		↑	↑ (weak)
APTT (sec)		↑	↑ (weak)
Fibrinogen	Clauss method	=	=
	Derived Fibrinogen	↓	=
Thrombin Time TT		=	=
Factor assays (clotting assays)		↓ ⁽¹⁾	↓ ⁽¹⁾ (weak)
Immunological assays (DDi, VWF: Ag, inhibitors, ...)		=	=
Anti-Xa activity (UFH or LMWH)		↑	↑
Antithrombin activity	FXa-based assay	↑	↑
	FIIa-based assay	=	=
Protein C activity	Chronometric assay	↑	↑
	Chromogenic assay	=	=
Protein S activity	Chronometric assay	↑	↑
	Free Protein S Ag ⁽²⁾	=	=
Lupus anticoagulant testing : "sensitive" APTT and dRVVT (screening, mixing, confirmation)		↑	↑
Screening for ACL and anti-β2GPI antibodies		=	=
Resistance to activated Protein C		↑	↑
FV Leiden mutation and 20210A mutation		=	=

Sources :

Rivaroxaban et tests de biologie médicale V1 Octobre 2012 - GEHT
 Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Gouin-Thibault et al. *Thromb Haemost.* 2013 Oct 31;111⁽²⁾.
 Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Douxfils et al. *Thromb Haemost.* 2013 Aug;110⁽²⁾:283-94. doi: 10.1160/TH12-12-0898. Epub 2013 Jun 13.

↑ : increase - ↓ : decrease
 "=" : no effect

(1) : decrease at high rivaroxaban concentrations
 (2) : some qualitative defects may need to be considered



Effects of dabigatran (Pradaxa®) on commonly used coagulation assays

Assays		Effects
PT (sec)		↑
APTT (sec)		↑
Fibrinogen	Clauss method	= / ↓
	Derived Fibrinogen	↓
Thrombin Time TT		↑
Factor assays (clotting assays)		↓
Immunological assays (DDi, VWF: Ag, inhibitors, ...)		=
Anti-Xa activity (UFH or LMWH)		=
Antithrombin activity	FXa-based assay	=
	FIIa-based assay	↑
Protein C activity	Chronometric assay	↑
	Chromogenic assay	=
Protein S activity	Chronometric assay	↑
	Free Protein S Ag ⁽²⁾	=
Lupus anticoagulant testing : "sensitive" APTT and dRVVT (screening, mixing, confirmation)		↑
Screening for ACL and anti-β2GPI antibodies		=
Resistance to activated Protein C		↑
FV Leiden mutation and 20210A mutation		=

agence2room - © 2014 Diagnostica Stago - All rights reserved - 10/2015 - Ref:28253
This document contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.

Source :

Dabigatran et examens de biologie médicale V2
March 2013 - GEHT

↑ : increase - ↓ : decrease
"=" : no effect

(2) : some qualitative defects may need to be considered


Stago
At the Heart of Haemostasis

Diagnostica Stago S.A.S.
RCS Nanterre B305 151 409
3, allée Thérèse
92600 Asnières sur Seine
France
Ph: +33 (0)1 46 88 20 20
Fax: +33 (0)1 47 91 08 91
webmaster@stago.com
www.stago.com